Navigation Links
New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients
Date:4/19/2012

BARCELONA, Spain, April 19, 2012 /PRNewswire/ --

Further data shows PegIFN-λ's comparable efficacy but better safety profile than PegIFN-α

New data presented at the International Liver Congress™ 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials[1],[2],[3],[4],[5],[6] confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

To view the Multimedia News Release, please click:

http://multivu.prnewswire.com/mnr/prne/easl/53808/ 

The following new studies cover the treatment of HCV patients with genotypes (GT) 1, 2 or 3, who were administered ribavirin (RBV) - without IFN - and either one or two other drugs: direct-acting antivirals - HCV nucleotide analogues, HCV protease inhibitors, non-nucleoside RNA polymerase inhibitors - or host-targeting antivirals - cyclophilin A inhibitor.

PROTON & ELECTRON

  • Lawitz E, et al 'PSI-7977 PROTON and ELECTRON: 100% concordance of SVR4 with SVR24 in HCV GT1, GT2, & GT3' and the related abstract Gane EJ, et al 'ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3'.
  • In Lawitz E, et al, 100% of HCV GT2 or 3 patients (10) achieved SVR4 after treatment with PSI-7977 and RBV. In Gane EJ, et al, of nine HCV GT1 prior null-responders treated with PSI-7977 and RBV for 12 weeks, 7 had undetectable levels of HCV RNA by week 2.

SOUND-C2

  • Zeuzem S, et al 'SVR4 and SVR12 with an INTERFERON-FREE regimen of BI201335 and BI207127, +/- RIBAVIRIN, in treatment-naïve patients with chronic genotype-1 HCV infection: interim results of SOUND-C2'.
  • Treatment-naïve GT1 HCV patients treated with a regimen of BI201335, BI207127 and RBV achieved 60% SVR12 after 16 weeks of treatment and up to 70% SVR4 after treatment with a lower BI207127 dose (600mg BID) for 28 weeks.


VITAL-1

  • Pawlotsky J-M, et al 'ALISPORIVIR plus RIBAVIRIN is highly effective as INTERFERON-FREE or INTERFERON-ADD-ON regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study' and the related abstract Alberti A, et al 'ALISPORIVIR (ALV) plus PEG-INTERFERON/RIBAVIRIN (PR) in HCV G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with PR'.
  • In Pawlotsky J-M, et al, 88% of treatment-naïve HCV GT2 or 3 patients achieved SVR 12 after treatment with Alisporivir and RBV. In Alberti A, et al, 70% of null non-responders achieved cEVR when treated with Alisporivir, IFN and RBV.

AI444040

  • Sulkowski M, et al 'Potent viral suppression with all-oral combination of DACLATASVIR (ns5a inhibitor) and GS-7977 (ns5b inhibitor), +/-RIBAVIRIN, in treatment-naïve patients with chronic HCV GT1, 2, or 3'
  • Treatment-naïve HCV GT1, 2, and 3 patients given an IFN- and RBV-free once-daily combination of DACLATASVIR and GS-7977 for 24 weeks achieved high rates of early virologic response (HCV RNA detectable at week 4 but undetectable at week 12   EVR) by mITT analysis: 97% EVR in GT1, 90% in GT2 and 3.

The combination of PegIFN-α and ribavirin (RBV) is the current standard of care for chronic HCV[7], but is associated with a number of side effects - including flu-like symptoms, psychiatric manifestations, autoimmune reactions, and hematologic toxicities.[8],[9] Between 20-40% of patients require a dose reduction or temporary interruption in their PegIFN-α and ribavirin (RBV) treatment[10] and in 10-14% of patients, side effects are so severe that treatment must be discontinued.[8],[9]

However, studies have shown that achieving a virologic response in chronic HCV is much more dependent on the dose of IFN-α[11]/PegIFN-α[12],[13],[14] than RBV[15],[16],[17],[11],[18]. As such, PegIFN-α free therapy is highly anticipated by healthcare professionals and patients alike.

EASL's Secretary General Professor Mark Thursz commented on the exciting new data being showcased at the congress: "In the future, patients can look forward to all oral treatment regimens with high success rates and low side effects. Furthermore, there is a large cohort of patients with more advanced liver disease who will now be able to access treatment that was previously impossible due to the side effects of Interferon-alpha. Over the last five years we have seen an evolution in HCV treatment, with direct antivirals used in combination with Pegylated Interferon and Ribavirin. Interferon-free regimes truly represent a revolution in treatment."

Separate data presented at the congress may provide a further option. New results from a phase IIb study[19] show a different form of interferon - pegylated Interferon-lambda (PegIFN-λ) - administered with RBV for 24 weeks in HCV GT2 & 3 patients gives comparable SVR24 (undetectable HCV RNA levels 24 weeks after treatment) to PegIFN-α-2a and RBV, but with fewer side effects (musculoskeletal and flu-like symptoms, hematologic toxicity) and dose modifications for PegIFN or RBV.

Professor Thursz commented: "It remains possible that a number of patients will still need interferon based therapy for their HCV infection. Interferon-lambda, with a better side effect profile, looks like an excellent option in this group of patients, who are likely to have more advanced disease."

Notes to Editors

About EASL

EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

EASL's main focus on education and research is delivered through numerous events and initiatives, including:

  • The International Liver Congress™ which is the main scientific and professional event in hepatology worldwide
  • Meetings including Monothematic and Special conferences, Post Graduate courses and other endorsed meetings that take place throughout the year
  • Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field of hepatology
  • Journal of Hepatology published monthly
  • Participation in a number of policy initiatives at European level
  • iLiver iPhone app - a free medical app developed by EASL, with content fully authored, validated and accredited by 42 independent liver specialists

About The International Liver Congress™ 2012

The International Liver Congress™ 2012, the 47th annual meeting of the European Association for the study of the Liver, is being held at the Centre Convencions Internacional (CCIB) in Barcelona from April 18 - 22, 2012. The congress annually attracts over 8,300 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.

References

1. Lawitz E, et al, PSI-7977 PROTON and ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3. Abstract presented at the International Liver Congress™ 2012.

2. Gane EJ, et al, ELECTRON: ONCE DAILY PSI-7977 PLUS RBV IN HCV GT1/2/3. Abstract presented at the International Liver Congress™ 2012.

3. Zeuzem S, et al, SVR4 and SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2. Abstract presented at the International Liver Congress™ 2012.

4. Pawlotsky J-M, et al, ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY. Abstract presented at the International Liver Congress™ 2012.

5. Alberti A, et al, ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR. Abstract presented at the International Liver Congress™ 2012.

6. Sulkowski M, et al, POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/-RIBAVIRIN, IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3. Abstract presented at the International Liver Congress™ 2012.

7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology 2011 vol. 55 245–264

8. Fried MW, et al, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.

9. Manns MP, et al, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65.

10. Jang JY and Chung RT, Chronic Hepatitis C. Gut Liver. 2011 June; 5(2): 117–132.

11. McHutchison JG, et al, Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002 Oct;123(4):1061-9.

12. Heathcote EJ, et al, Re-treatment of chronic hepatitis C with consensus interferon. Hepatology. 1998 Apr;27(4):1136-43.

13. Lindsay KL, et al, A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395–403.

14. Reddy KR, et al, Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001;33:433–438.

15. Shiffman ML, et al, Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology. 2007;46:371–379.

16. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62:699–709.

17. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132:103–112.

18. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355.

19. Zeuzem S, et al, PEGINTERFERON LAMBDA-1a (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAÏVE PATIENTS WITH HCV GENOTYPES (G) 2 or 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB. Abstract presented at the International Liver Congress™ 2012.

 



For further information on the studies, or to request an interview, please do not hesitate to contact the EASL Press Office on:

Email: easlpressoffice@cohnwolfe.com
 
Travis Taylor   Onsite tel: +44(0)7894-386-422

Vicky O'Connor  Onsite tel: +44(0)7894-386-428



Video: http://multivu.prnewswire.com/mnr/prne/easl/53808/


'/>"/>
SOURCE European Association for the Study of the Liver
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Journal Article Suggests DermaClose® RC Used in Combination With VAC Therapy Can Dramatically Reduce the Need for Skin Grafting of Fasciotomy Wounds for Combat Related Trauma
2. Grifols Study Suggests Repeated Plasmapheresis May Reduce "Bad" LDL Cholesterol Levels While Increasing "Good" HDL Cholesterol Levels in Some Individuals
3. New Research Suggests That Acthar Reduces Proteinuria in Idiopathic Membranous Nephropathy In Part Through Suppression of Anti-PLA2R Antibodies
4. TRiUS Data Suggests That Testim® Significantly Improved Sexual Function in Hypogonadal Men
5. Help Remedies Suggests People TAKE LESS
6. Research Suggests FORTEO® Significantly Increases Bone Strength
7. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
8. Leading Rehab Facility Urges Patients Not to Stop Taking Antidepressants After New Study Suggests Increased Risk of Heart Attacks and Strokes
9. New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
10. Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate
11. Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... YORK , July 26, 2017 The ... Annual Prix Galien USA Award Nominees. ... the Prix Galien Award recognizes outstanding biomedical and technology product ... To qualify, each candidate must be U.S. ... last five years and demonstrate tremendous potential to impact human ...
(Date:7/24/2017)... N.Y. , July 24, 2017 IBM (NYSE: ... the Gartner Magic Quadrant for Solid-State Arrays (SSA) for the ... According to Gartner, "Vendors in the Leaders ... and Completeness of Vision. A vendor in the Leaders quadrant ... needed to drive the acceptance of new technologies. These vendors ...
Breaking Medicine Technology:
(Date:8/16/2017)... NJ (PRWEB) , ... August 16, 2017 , ... With low back pain afflicting 8 ... know what causes its kissing cousin – upper back pain. But this equally vexing condition ... treatment options, according to Kaixuan Liu, MD, PhD , founder and president of Atlantic ...
(Date:8/15/2017)... ... August 15, 2017 , ... Western University of ... WesternU will move forward in bold new directions while using its foundational values ... ceremony with Convocation, the traditional opening of the academic year, on August 12, ...
(Date:8/15/2017)... ... August 15, 2017 , ... An August 2 ... into a coma and died after receiving silicone injections for buttock augmentation, performed ... the alleged perpetrator’s apartment after the victim was fetched from a neighborhood Dunkin ...
(Date:8/15/2017)... ... August 15, 2017 , ... Local dentist, Dr. Kenneth Nash, ... in orthodontics, dental crowns and teeth whitening near Jackson, MS may ... at his state-of-the-art practice, Nash Family Dentistry, in order to offer his patients ...
(Date:8/15/2017)... ... August 15, 2017 , ... AVIE! MedSpa and Laser Center ... areas of the body like the arms and inner thighs easier to treat. ... for their CoolSculpting treatments, which cuts treatment times in half to as little ...
Breaking Medicine News(10 mins):